Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
On Thursday, P3 Health Partners Inc (NASDAQ:PIII), currently valued at $63.91 million, disclosed its fourth-quarter financial results for 2024, which showed revenues and adjusted EBITDA falling short of analyst expectations. BTIG maintained a Neutral rating on the company’s stock following the report. According to InvestingPro data, the company has been quickly burning through cash, with trailing twelve-month EBITDA at -$166.08 million.
The healthcare provider reported revenue of $370.7 million, reflecting a 7% year-over-year increase but failing to meet BTIG and consensus estimates of $389.5 million and $378 million, respectively. While the company has shown strong revenue growth of 25.38% over the last twelve months, its gross profit margin remains weak at -2.72%. The adjusted EBITDA loss of $67.6 million was also more significant than BTIG and consensus estimates, which anticipated losses of $25.5 million and $28 million, respectively.
P3 Health Partners pointed out that around $29 million in one-time costs, partly due to rectifying certain accounting procedures, impacted the quarter’s financials. Even after accounting for these costs, the adjusted EBITDA loss stood at approximately $38 million, still below market expectations.
Despite the earnings miss, P3 Health Partners confirmed its guidance for 2025 across all metrics and slightly raised its membership guidance. The company expressed confidence in achieving an incremental EBITDA benefit of over $130 million. However, the projected guidance for an adjusted EBITDA between a loss of $35 million and a gain of $5 million was deemed optimistic by BTIG. InvestingPro analysis reveals concerning liquidity issues, with a current ratio of 0.53 indicating short-term obligations exceed liquid assets. Get access to 8 more key ProTips and comprehensive analysis with an InvestingPro subscription.
The analysis highlighted some areas of improvement, such as better utilization in certain segments of the business. Nonetheless, concerns were raised about increasing unit costs and the overall limited visibility into the company’s future performance. The stock has experienced a significant decline of 82.45% over the past year, reflecting these challenges. Given the competitive and challenging nature of the Medicare Advantage space, BTIG expressed caution regarding P3 Health Partners, emphasizing the need for substantial positive EBITDA and cash flow before adopting a more favorable outlook. Discover more insights about PIII’s valuation and growth potential in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, P3 Health Partners reported its fourth-quarter 2024 earnings, revealing an adjusted loss per share of $0.36, which was significantly wider than the anticipated loss of $0.19. The company’s revenue for the quarter was $371 million, slightly below the expected $378.06 million. Despite these setbacks, P3 Health Partners reaffirmed its guidance for 2025, projecting revenues between $1.35 billion and $1.5 billion and a medical margin of $174 million to $210 million. The company remains optimistic about achieving profitability in 2025, driven by strategic initiatives and improvements in the Medicare sector.
Additionally, P3 Health Partners showed a year-over-year revenue growth of 18% for the full year 2024, reaching $1.5 billion, although its medical margin decreased by 37% to $85.5 million. The firm also reported an adjusted EBITDA loss of $167.2 million. In other developments, the company is focusing on expanding capitation contracts and new programs, which could potentially impact its financial performance positively. The company’s leadership highlighted the positive impact of new management on staff morale and the expected benefits from Medicare sector improvements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.